Innovation Zed, a leading Irish R&D company specialising in innovative medical devices, announces its strategic partnership with Enhance-D, a Swiss company dedicated to enhancing diabetes and exercise management through its digital health platform.
Innovation Zed announced this week that it entered into a strategic partnership with Enhance-D to optimize diabetes therapy.
Switzerland-based Enhance-D develops a digital health platform for enhancing diabetes and exercise management. It designed its platform to empower people with diabetes through cutting-edge technologies and personalized solutions.
Ireland-based Innovation Zed develops insulin dosing technology, including the InsulCheck DOSE add-on device for pen injectors.
Through their partnership, the two companies aim to integrate Innovation Zed’s DOSE technology into the Enhance-D platform. DOSE, the company’s third-generation technology (marketed as InsulCheck) captures and stores insulin injection data. “We are very happy to collaborate with the team behind Enhance-D and advance our shared commitment to improve diabetes management,'' said Dr. Dean Minnock, CEO of Innovation Zed. “By integrating our InsulCheck DOSE technology into Enhance-D’s innovative platform, we aim to empower users and their caregivers with real-time data and personalized support around exercise, ultimately improving their quality of life.”
Innovation Zed says Enhance-D’s goals of redefining diabetes care align seamlessly with its vision of leveraging technology to enhance patient outcomes.
“This partnership with Innovation Zed represents a significant moment for us at Enhance-D,” CEO Federico Fontana said. “It’s more than just a collaboration; it’s a shared vision to revolutionize diabetes management around exercise by harnessing the power of integrated technologies. Through our combined efforts, we are working for a future where managing exercise and diabetes is more intuitive, efficient, and aligned with our users’ lifestyles.”